Keyboard and Mouse Carrying Disease

 

Medizone International, Inc. (OTCBB and OTCQB: MZEI) (http://medizoneint.com)

Researchers in Taiwan found computer keyboards and computer mice harbor pathogens — including Methicillin resistant Staphylococcus aureus.

However, the researchers suggest few infections can be traced to the computers.

The research team, led by Yen-hsu Chen of Kaohsiung Medical University Hospital in Taiwan, looked at computer equipment in a 1,600-bed hospital with 282 computers. They found 17.4 percent contamination rate of S. aureus, Acinetobacter spp. or Pseudomonas spp.

Doctors and nurses go from patient to keyboard without washing their hands, said a consultant microbiologist Dr Peter Wilson. That’s quite understandable because you would wash your hands between patients but not between a patient and a keyboard.

The contamination rates of MRSA and A. baumannii in the ward computers were 1.1 percent and 4.3 percent, respectively. No P. aeruginosa was found.

“No clinical correlation of contamination of these computer devices to clinical isolates was found,” Chen said in a statement. “Routine disinfection and even surveillance of these computer devices may not be mandatory in non-outbreak settings.”

The findings are reported in Biomedcentral’s or BMC Infectious Diseases.

Medizone International, Inc. is a research and development company engaged in developing its AsepticSure™ System to decontaminate and sterilize hospitals, sports training facilities, schools and other critical infrastructure. A government variant is being developed for bio-terrorism counter measures. Successful decontamination by AsepticSure™ to the 6 log standard or greater has been demonstrated with C.difficile, E coli, Pseudomonas aeruginous, MRSA, VRE and Bacillius subtilis.

Medizone International, Inc.
Post Office Box 742
Stinson Beach, CA 94970
Telephone: 415-868-0300
Fax: 415-868-2344

This release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.

Share and Enjoy:
  • Print
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google Bookmarks
  • Blogplay
  • Add to favorites
  • Diggita
  • email
  • RSS
  • StumbleUpon
  • 豆瓣
  • 豆瓣九点

Post to Twitter Tweet This Post

Tags:

 
 
 

Comments are closed.